dfda compounded glp-1 receptor agonists Pharmacovigilance Assessment of Agonists: Insights From the FDA Adverse Event Reporting System What Are Compounded GLP-1 Medications?

DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes Mellitus (T2DM) and is based on promoting the incretin effect

The majority of T2D management is in primary care, where clinicians (medical, nursing and pharmacist staff) play an important role in addressing patient needs and achieving treatment goals

Compare Mounjaro vs Ozempic to understand their differences, benefits, and effectiveness in medical weight management.

Individualization is Key: The ADA strongly advocates tailoring HbA1c goals based on: Duration of diabetes Risk of hypoglycemia Life expectancy Comorbidities (cardiovascular disease, CKD) Patient preference and treatment burden Beyond HbA1c: Modern diabetes care increasingly integrates Continuous Glucose Monitoring (CGM) metrics such as Time in Range (TIR) alongside HbA1c

Considerations regarding adverse effects and contraindications for different drug classes are provided to help guide treatment decision-making when considering pharmacotherapy for weight management in patients with obesity.

Within 48 hours, multiple Indian companies launched cheaper versions